|
|
|
| Effect of Cinacalcet in patients with secondary hyperparathyroidism of chronic kidney disease maintenance dialysis |
| JIANG Zhiyuan1 ZHANG Ru1 LI Longhai2 |
1.Department of Pharmacy, Fuyang Second People’s Hospital, Anhui Province, Fuyang 236000, China;
2.Department of Nephrology, Fuyang Second People’s Hospital, Anhui Province, Fuyang 236000, China |
|
|
|
Abstract Objective To explore and analyze the clinical effect of Cinacalcet in patients with secondary hyperparathyroidism (SHPT) of chronic kidney disease maintenance dialysis. Methods A total of 120 SHPT patients with chronic kidney disease maintenance dialysis admitted to Fuyang Second People’s Hospital, Anhui Province from January 2019 to April 2020 were selected as study subjects. According to odd number and even number method, they were divided into control group and experimental group, with 60 patients in each group. The control group was treated with conventional drugs such as vitamin D analogues and phosphorus binders, the experimental group was treated with Cinacalcet on the basis of the control group, and both groups were treated for three months. The laboratory test results (levels of serum calcium [Ca], serum phosphorus [P], calcium-phosphorus product [Ca×P], serum whole parathyroid hormone [iPTH]) were compared between the two groups before and after treatment. The incidence of adverse reactions and clinical efficacy were compared between the two groups. Results The levels of Ca, P, Ca×P and iPTH in the two groups were lower than those before treatment, and the levels of Ca, P, Ca×P and iPTH in the experimental group were lower than those in the control group (all P ＜ 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). The clinical total effective rate of the experimental group was higher than that of the control group, the difference was statistically significant (P ＜ 0.05). Conclusion Cinacalcet can effectively reduce the levels of Ca, P, Ca×P and iPTH in SHPT patients with chronic kidney disease and maintenance dialysis, and improve the clinical efficacy without increasing the adverse drug reactions.
|
|
|
|
|
|
[1] 王赫男，郭增玉，王超民，等.西那卡塞治疗血液透析患者继发性甲状旁腺功能亢进的疗效与安全性观察[J].中国中西医结合肾病杂志，2016，17（7）：625-626.
[2] 王娟，郝丽，张晶晶，等.西那卡塞治疗肾性继发性甲状旁腺功能亢进的临床疗效[J].中国新药与临床杂志，2016， 35（12）：70-74.
[3] 田媚.西那卡塞联合小剂量骨化三醇治疗终末期肾脏病继发性甲状旁腺功能亢进的疗效分析[J].安徽医药，2018， 22（6）：1163-1166.
[4] 汪涛，彭瑾，何冬梅，等.西那卡塞联合小剂量骨化三醇治疗透析患者继发性甲状旁腺功能亢进疗效观察[J].陕西医学杂志，2018，47（12）：119-123.
[5] 刘学公.甲状腺功能亢进症的诊断与治疗[M].北京：中国科学技术大学出版社，2002.
[6] 费良玉，李浩，张宝文.西那卡塞联合骨化三醇对血液透析患者难治性继发性甲状旁腺功能亢进的干预研究[J].中国医师杂志，2018，20（4）：584-586.
[7] 郝国强，邢壮杰，邓芝徽，等.继发性甲状旁腺功能亢进行甲状旁腺全切除术后低钙血症的防治[J].安徽医药，2019，23（10）：1998-2000.
[8] Chen J，Kong X，Jia X，et al. Association between metabolic syndrome and chronic kidney disease in a Chinese urban population [J]. Clinica Chimica Acta，2017，47（3）：103-108.
[9] 罗贞，史添立，周君，等.西那卡塞联合小剂量骨化三醇治疗透析患者继发性甲状旁腺功能亢进的疗效观察[J].临床肾脏病杂志，2017，17（7）：431-434.
[10] 王琦，艾常虹，商庆辉.西那卡塞治疗继发性甲状旁腺功能亢进症的研究进展[J].中国药房，2017，28（23）：3310-3312.
[11] 余文洪，孙岩，卓燕.尿毒症患者继发甲状旁腺功能亢进合并甲状腺癌的临床特点及诊治[J].重庆医学，2017， 46（25）：3589-3590.
[12] 罗佳佳，褚以德，李瑜琳.慢性肾脏病微炎症状态及其与营养不良关系的研究进展[J].山东医药，2016，56（14）：107-109.
[13] 孟庆阳，张炜.慢性肾脏病患者骨代谢标志物血清水平及相关性[J].中国公共卫生，2019，35（7）：854-856.
[14] Warady B ，Iles JN，Ariceta G，et al. A randomized，double-blind，placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis [J]. Pediatric Nephrology，2019，34（3）：475-486.
[15] 王艳，阮华玲，李毅，等.甲状腺功能亢进患者甲状腺功能、自身抗体、骨密度及骨代谢指标变化分析[J].海南医学院学报，2016，22（13）：1418-1421.
[16] 陈燕，张英姿，姚霞娟，等.帕立骨化醇与骨化三醇治疗尿毒症血透患者继发性甲状旁腺功能亢进症的疗效比较[J].中国现代医生，2020，58（34）：52-54，59.
[17] 张涛静，吴淑馨，谢培凤.Graves病合并继发性甲状旁腺功能亢进症1例[J].中国医药导报，2016，13（29）：165-166.
[18] 卢志芳，杨先凯.血清全段甲状旁腺激素和生物活性全段甲状旁腺激素检测的相关性分析[J].中西医结合心血管病电子杂志，2016，7（33）：1667-1669.
[19] 范佳妮，林明增，陈璐.西那卡塞联合骨化三醇对血液透析继发性甲状旁腺功能亢进患者的疗效观察[J].中国现代医生，2020，58（24）：116-119.
[20] 王垚，于博，魏巍，等.西那卡塞联合小剂量骨化三醇治疗血液透析患者继发性甲状旁腺功能亢进的疗效观察[J].中国中西医结合肾病杂志，2018，19（5）：435-437.
[21] 周露，赵文琪，叶婷，等.西那卡塞联合活性维生素D治疗维持性血液透析继发性甲状旁腺功能亢进症的疗效观察[J].中国中西医结合急救杂志，2017，23（24）：653.
[22] 赵沙沙，闻萍，甘巍，等.继发性甲状旁腺功能亢进症甲状旁腺切除术后并发症分析[J].肾脏病与透析肾移植杂志，2019，28（1）：25-29.
[23] 朱丽娇，徐承云，刘欣，等.慢性肾脏病患者甲状旁腺激素与肾性贫血的关系[J].广东医学，2018，39（14）：150-153.
[24] 杨晓琦，陈安举，王田田，等.继发性甲状旁腺功能亢进甲状旁腺全切除术的探讨[J].中华耳鼻咽喉头颈外科杂志，2020，55（2）：98-103.
[25] 许颖波，马瑜智，张娟，等.西那卡塞治疗血液透析患者继发性甲状旁腺功能亢进症的临床研究[J].基因组学与应用生物学，2020，39（1）：305-312.
[26] 於建根，杨爱华，张小云，等.西那卡塞联合高通量透析治疗中重度继发性甲状旁腺功能亢进的临床研究[J].中国当代医药，2021，28（3）：45-47.
[27] 梁馨苓，徐丽霞.拟钙剂在维持性血液透析患者的应用体会[J].肾脏病与透析肾移植杂志，2020，29（3）：55-56. |
|
|
|
